Key Insights

Highlights

Success Rate

93% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.7%

3 terminated out of 64 trials

Success Rate

93.3%

+6.8% vs benchmark

Late-Stage Pipeline

22%

14 trials in Phase 3/4

Results Transparency

17%

7 of 42 completed with results

Key Signals

7 with results93% success

Data Visualizations

Phase Distribution

45Total
Not Applicable (21)
Early P 1 (2)
P 1 (1)
P 2 (7)
P 3 (7)
P 4 (7)

Trial Status

Completed42
Unknown12
Terminated3
Withdrawn3
Recruiting2
Not Yet Recruiting1

Trial Success Rate

93.3%

Benchmark: 86.5%

Based on 42 completed trials

Clinical Trials (64)

Showing 20 of 20 trials
NCT04700202CompletedPrimary

Identifying Risk Factors for Gram-negative Resistance for HAP/VAP in the Intensive Care Unit

NCT07482007Not ApplicableActive Not RecruitingPrimary

Oropharyngeal Care With Colostrum, Chlorohexidine and Sodium Bicarbonate in Preventing Ventilator-associated Pneumonia in Preterm Neonates

NCT05918172CompletedPrimary

Comparison of the Frequency of Ventilator-Associated Pneumonia in Intubated Patients Followed Up With Automatic Cuff Pressure Controller and Manual Cuff Pressure Controller in Pediatric Intensive Care

NCT07436780Not Yet RecruitingPrimary

B Lymphocyte Populations in the Pulmonary Microenvironment of Patients Under Mechanical Ventilation With or Without VAP (Ventilator-Associated Pneumonia)

NCT07013032RecruitingPrimary

Diagnostic and Prognostic Value of Reticulated Platelet Fraction in Ventilator-Associated Pneumonia (REPLAY-VAP)

NCT07149909Not ApplicableCompletedPrimary

Fiberoptic Bronchoscopy in Severe Ventilator-associated Pneumonia

NCT06168734Phase 3WithdrawnPrimary

Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP

NCT06066736CompletedPrimary

Risks Factors and Outcome of Recurrences in Patients With Ventilator-Associated Pneumonias (REVAP)

NCT05589727CompletedPrimary

Application of Ventilator-Associated Events (VAE) in Ventilator-Associated Pneumonia (VAP) Notified in Brazil

NCT04882085Phase 4Completed

Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults

NCT03581370Phase 3RecruitingPrimary

Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients with Ventilator Associated-pneumonia

NCT05877105Not ApplicableCompleted

Effect of Selected Evidence-based Practices and Related Nurses' Education on the Incidence and Severity of Ventilator-associated Pneumonia

NCT06118242Not ApplicableUnknownPrimary

The Effect of Solutions Used in Oral Care on Preventing Ventilator-Associated Pneumonia.

NCT06076603Unknown

Comparison of Epithelial Lining Fluid and Blood Pharmacokinetics and Pharmacodynamics of Intravenous and Intravenous Plus Nebulized Polymyxin B in Multidrug Resistant Bacteria Ventilator-associated Pneumonia Patients

NCT05877625Unknown

Study on Dynamic Environmental Exposome of ICU and the Establishment of Microbial Transmission Model Between Environment and Host

NCT02116699Not ApplicableCompleted

Oropharyngeal Administration of Mother's Colostrum for Premature Infants (NS-72393-360)

NCT05450796UnknownPrimary

Prognosis and Virulence Determination of Capsule and Endotoxin During Klebsiella Spp. Ventilator-associated Pneumonias

NCT02634411Not ApplicableCompletedPrimary

Impact of the Duration of Antibiotics on Clinical Events in Patients With Pseudomonas Aeruginosa Ventilator-associated Pneumonia (iDIAPASON)

NCT02583308Not ApplicableCompletedPrimary

Impact of the Subglottic Secretions Drainage on the Tracheal Secretions Colonisation

NCT02585180Not ApplicableCompletedPrimary

Subglottic Secretions Surveillance to Predict Bacterial Pathogens Involved in Ventilator-associated Pneumonia

Scroll to load more

Research Network

Activity Timeline